Approxima

Honored to have presented the latest updates on Approxima at #LSIEurope24 last week in Sintra, Portugal. It was an incredible opportunity to showcase the progress and milestones our team has achieved, while connecting with medtech innovators at the LSI event. Excited for what's to come! #Medtech #tricuspidvalve #tricupsidregurgitation #approxima

Approxima (#LSIEurope24 Innovator) is a Medtech startup developing a percutaneous right ventricular reshaping device to treat tricuspid regurgitation. This approach uniquely addresses the root cause of tricuspid valve regurgitation — right ventricular dilation — while making all bailout options feasible and ensuring a short, safe, straightforward implantation procedure. Approxima has reached significant milestones, including: • Raised €1.6M in a seed round led by #LSIAlumni Panakes Partners and is now beginning to raise its Series A (February 2023) • Improved device design allowing for totally percutaneous implantation procedure successfully demonstrated in in-vivo animals • Robust in-vivo preclinical data (> 20 animals) on efficacy in a pathological model and safety in a chronic model • Named TOP INNOVATION at PCR London Valve 2023, the clinical community broadly accepts the approach, and internationally recognized KOLs in the structural heart field are involved • Looking ahead, its linear development strategy aims for a first-in-human clinical trial in 2026, followed by EFS and a pivotal study to secure regulatory approvals in the EU and US. We’re excited to announce that Co-Founder & CEO, Michal Jaworek has been selected to present Approxima at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Michal and learn more about Approxima.

We are honoured to announced that the Scientific Board of Approxima has been joined by two interventional cardiologists distinguished KOLs in the structural heart field: - Prof. Nicolas Van Mieghem - Full Professor of Inteventional Cardiology at Erasmus MC in Rotterdam, Netherlands - Dr. Federico De Marco - Director of Interventional, Valvular and Structural Heart Cardiology at Centro Cardiologico Monzino in Milan, Italy   They have been collaborating with us for some time now, supporting Approxima's efforts toward the development of a totally percutaneous implantation procedure. We are excited to share this news with our LinkedIn community and look forward to keeping you updated on the progress. Stay tuned!

🚀 STARTUP IN EVIDENZA - #4EPISODIO 🚀 ▶Oggi parliamo di Approxima, una promettente startup Medtech nata come spin-off del Politecnico di Milano. Approxima sta rivoluzionando il trattamento dell'insufficienza tricuspidale con un innovativo dispositivo medico impiantabile. 🫀𝐋'𝐢𝐧𝐬𝐮𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐳𝐚 𝐭𝐫𝐢𝐜𝐮𝐬𝐩𝐢𝐝𝐚𝐥𝐞: 𝐮𝐧𝐚 𝐬𝐟𝐢𝐝𝐚 𝐦𝐞𝐝𝐢𝐜𝐚 𝐠𝐥𝐨𝐛𝐚𝐥𝐞 Questa patologia cardiaca colpisce oltre 13 milioni di persone nel mondo, con un impatto particolarmente significativo su anziani e donne. Ogni anno, più di 250.000 nuovi casi severi vengono diagnosticati solo in Europa e Stati Uniti. La malattia, causata principalmente dalla dilatazione del ventricolo destro, comporta una mancata chiusura della valvola tricuspide ed è associata ad un tasso di mortalità del 36% entro un anno dalla diagnosi. Attualmente, la maggior parte dei pazienti non è considerato idoneo alla chirurgia a cuore aperto, lasciando molti senza opzioni terapeutiche efficaci. 💡 𝐋𝐚 𝐬𝐨𝐥𝐮𝐳𝐢𝐨𝐧𝐞 𝐀𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚: 𝐢𝐧𝐧𝐨𝐯𝐚𝐳𝐢𝐨𝐧𝐞 𝐚𝐥 𝐬𝐞𝐫𝐯𝐢𝐳𝐢𝐨 𝐝𝐞𝐢 𝐩𝐚𝐳𝐢𝐞𝐧𝐭𝐢 Il dispositivo sviluppato da Approxima offre una soluzione concreta: • È un sistema di riparazione della valvola tricuspide totalmente percutaneo, ideale per pazienti ad alto rischio chirurgico. • Si basa su un approccio distintivo di rimodellamento ventricolare, affrontando la causa principale dell'insufficienza. • Mantiene aperte tutte le opzioni di intervento future, posizionandosi come trattamento di prima scelta. • Offre una procedura di impianto efficace, semplice e riproducibile. 🏆 𝐑𝐢𝐜𝐨𝐧𝐨𝐬𝐜𝐢𝐦𝐞𝐧𝐭𝐢 𝐞 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢 • Dati preclinici eccellenti dimostrano l'efficacia e la sicurezza della tecnologia. • Riconosciuta come TOP INNOVATION 2023 al prestigioso congresso PCR London Valve. • Scientific Board arricchito da Key Opinion Leaders internazionali e italiani in cardiologia interventistica. 🔜 𝐈𝐥 𝐟𝐮𝐭𝐮𝐫𝐨 𝐝𝐢 𝐀𝐩𝐩𝐫𝐨𝐱𝐢𝐦𝐚 La startup sta svolgendo gli studi preclinici e si prepara ad avviare trial clinici in Europa e Stati Uniti per dimostrare la sicurezza e l'efficacia della tecnologia sull'uomo. #Approxima rappresenta un esempio brillante di come l'innovazione Made in Italy possa avere un impatto globale nel campo della salute, offrendo nuove speranze a milioni di pazienti in tutto il mondo. 🔗Per approfondire: https://lnkd.in/dRY-3UwY 📌#MedTech #InnovazioneMedica #CardiologiaInterventistica #ClubdegliInvestitori #StartupInEvidenza Michal Jaworek Edoardo Maroncelli

We are delighted to inform you that Dr. Paolo Denti, our Chief Medical Officer, will be presenting the latest advancements of the Approxima technology at the upcoming #InnovatorsDay and #EuroPCR conference in Paris next week! 🔍 Our ePoster will be displayed throughout the duration of both Innovators Day and Euro PCR on touchscreens, offering attendees unlimited access to review our recent preclinical results including valuable insights into the efficacy of our technology in treatment of TR. For the first time ever (❗), we will be sharing the results from our pilot chronic study, marking a significant milestone towards the first in man clinical trial. 📅 Save the date and, if you wish to know more, reach out Paolo Denti, Michal Jaworek and Edoardo Maroncelli representing Approxima at the event.

Approxima is currently participating in the MedTech Strategist Innovation Summit in Dublin 2024, a remarkable event for #medtech innovations! Reach out to Michal Jaworek, who is representing Approxima, to discover more about our technology for tricuspid valve! #medtech #medtechstrategists #tricuspid #ventricularreshaping #approxima

🚀🚀🚀 We are thrilled to announce that Approxima has been selected as one of the top innovators in the medtech industry, earning us a spot to showcase our technology at the prestigious MedTech Innovator Road Tour 2024 in Dublin on April 15, during the International Pitch Event. Our CEO and Co-founder, Michal Jaworek, will be representing Approxima at the event and will also participate in the MedTech Strategist Innovation Summit in Dublin. Please reach out if you are interested in learning more about the right ventricular reshaping technology for the treatment of tricuspid regurgitation. We look forward to connecting with you! #MedTechInnovator #MedtechStrategist #tricuspid #ventricularreshaping #approxima

Exciting news! Approxima was chosen as one of the ten startups to pitch at Medtech Pitch Day organized by HTGF | High-Tech Gründerfonds in Munich, Germany today. It was an honor to participate in this prestigious event and engage with the German medtech ecosystem. #approxima #tricuspid #tricuspidregurgitation #medtech #structuralheart

Exciting news! Approxima was chosen as one of the ten startups to pitch at Medtech Pitch Day organized by HTGF | High-Tech Gründerfonds in Munich, Germany today. It was an honor to participate in this prestigious event and engage with the German medtech ecosystem. #approxima #tricuspid #tricuspidregurgitation #medtech #structuralheart

We are taking a moment to look back at #2023 and share the highlights of what has been a fantastic year! We are grateful and honoured to count on the support of a terrific team! After welcoming Giulia Pisoni and Martina Bernini earlier this year, also Annalisa Dimasi and Silvia Bonomi joined us as senior R&D engineer and junior quality R&D engineer, respectively. Annalisa holds a PhD in Bioengineering from Politecnico di Milano and has 5+ years of experience in the testing and verification of medical devices in the cardiovascular field. Silvia just got her master degree in Biomedical Engineering from Politecnico di Milano, with a focus on vascular applications and is eager to contribute to the development of the Approxima device ensuring compliance with relevant standards and regulations. Also, we would like to acknowledge for the unprecedented support received from our board of advisors, scientific board, and executive collaborators that are igniting our activities with participation, guidance and passion. This ensemble enabled us to reach the goal of starting in-vivo preclinical activities and preliminarily demonstrating the potential of our repair system for tricuspid regurgitation treatment based on right ventricular reshaping approach in terms of safety and efficacy. Our effort has brought us to be included in the #topinnovations of 2023 at PCR London Valves and we are looking forward to confirming promising results as we work through the preclinical verification path. We are sending warm wishes to every friend and colleague in our network for a wonderful holiday season and happy new year! The #Approxima team (Picture taken during our outing in Bergamo at the exhibition “SVALVOLATI – La chirurgia del cuore, un viaggio nel tempo” organized in the context of #BGBS2023) #tricuspidvalve #repairsystem #ventricularreshaping #team #structuralheart #seasonalgreetings